Refine by
Inflammatory Disorder Articles & Analysis
21 news found
Galapagos NV (Euronext & NASDAQ: GLPG) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted PRAC’s recommendation to add measures to minimise risk of serious side effects with JAK inhibitors for chronic inflammatory disorders. “JAK inhibitors ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
-Shareholder-Letter-220406.pdf Research reported in this publication was supported by the National Institute Of Neurological Disorders And Stroke (NINDS) of the National Institutes of Health (NIH) under Award Number R42NS120548. ...
“We believe that CAR-Tregs are the next frontier of cell therapy and represent a potentially transformational approach to solid organ transplantation as well as to many challenging autoimmune and inflammatory conditions. The STEADFAST Phase 1/2 study is an important milestone for genomic medicine that we anticipate will yield insights regarding CAR-Treg biology and could ...
Do not administer ABECMA to patients with active infection or inflammatory disorders. Treat severe or life-threatening CRS with tocilizumab or tocilizumab and corticosteroids. ...
Award of NIH Grant to Support Extrahepatic RNA Delivery in Inflammatory Disorders The Company's U.S. subsidiary, Altamira Therapeutics Inc., was recently awarded a Small Business Technology Transfer (STTR) grant by the National Institutes of Health (NIH) to help address the lack of effective systemic delivery technologies for RNA structures that might target ...
“This is a key achievement in support of our ultimate goal of providing a motility solution that localizes the sources and identifies the nature of GI disorders.” Gastrointestinal (GI) motility is the underlying factor in a wide range of disorders and dysfunction experienced by tens of millions in the U.S. GI disorders include ...
BOSTON--(BUSINESS WIRE)-- DermBiont, Inc., a clinical-stage biotechnology company developing targeted topical therapeutics that address the root causes of skin diseases, announced today that it has raised a $28 million Series A2 financing in parallel with the acquisition of clinical-stage biotechnology company Chromaderm, which is developing a topical inhibitor of melanin production as a ...
The CCL2/CCR2 pathway plays an important role in oncology, inflammatory, metabolic, and neurological disorders. Using its proprietary drug discovery technology, Orion successfully completed the development of OB-004 from target identification to lead optimization in only 6 months, a significant reduction in discovery time compared to industry averages. ...
Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune regulator, and has the potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-tosevere atopic dermatitis. By targeting OX40-Ligand, amlitelimab aims to restore immune homeostasis between ...
“Chemotherapy-induced peripheral neuropathy (CIPN) is a real problem worldwide and a window into what real unmet needs are in treating chronic and neuropathic pain, as well as reducing the use of opioids in CIPN and many other inflammatory pain related diseases and disorders. We are extremely grateful to the entire NIH-NINDS, the HEAL Initiative committee, ...
“Today’s agreement with INNERVIA Bioelectronics gives Merck access to a unique technology that increases energy efficiency in neurostimulators and could therefore become a true enabler for digital personalized treatment of patients suffering from severe and chronic diseases such as inflammatory disorders.” Both partners will closely ...
Our evidence also found that this formulation targeted a specific nuclear cellular receptor involved in anti-inflammatory mechanisms indicating that this formula may also treat inflammatory disorders. ...
“Our research also indicates that modifications to the cSOFA score may be used as severity measures for other illnesses, such as flu, sepsis and other inflammatory ...
A second program targeting gut barrier function with potential relevance for inflammatory bowel disease (IBD) and several other diseases is anticipated to enter the clinic soon after. In addition, the company continues to advance a broad portfolio of programs for gastrointestinal, CNS, and inflammatory disorders. “Kallyope pursues programs ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that the United States Patent and Trademark Office (USPTO) has issued a patent covering the use of the Company’s ...
("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the expansion of its Board of Directors with the appointments of (i) Professor Klaus Dugi, Executive Vice President and Chief Medical Officer ...
AOBiome Therapeutics ("AOBiome"), a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other systemic diseases, today announced the election of Jun Wang, Ph.D., founder and CEO of iCarbonX, as Chairman of AOBiome's Board of Directors, effective May ...
An altered microbiome has been associated with several different life-style diseases such as obesity, type 2 diabetes and inflammatory bowel disorder. In general, these diseases are characterized by reduced microbial diversity. ...
Our goal is to make this year's theme, You Can Control Your Asthma, not just a slogan but a reality. Asthma is a chronic inflammatory disorder of the airways, affecting more than 17 million American adults and 7 million children under 18 years of age. Asthma disproportionately affects minorities, people with lower incomes, females, and children. The ...